ArticleORL; journal for oto-rhino-laryngology and its related specialties2026
Vitamin A-Containing Intranasal Drops Improve Odour Detection Threshold.
Article in ORL; journal for oto-rhino-laryngology and its related specialties, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRetinoic acid, a metabolite of vitamin A (VA), has been shown in animal work to support olfactory receptor neuron regeneration. A limited amount of clinical research has also demonstrated potential therapeutic benefit in patients with olfactory dysfunction (OD). We therefore performed, to our knowledge, the first prospective study investigating whether the intranasal VA-containing "Coldastop" is beneficial in treating patients with non-sinonasal OD.
methodsA non-blinded prospective comparative study was performed, in patients with OD due to post-infectious, post-traumatic, and idiopathic aetiologies. Patients were treated with olfactory training (OT) alone, OT plus intranasal VA (Coldastop, OT+VA), or OT plus intranasal steroids (mometasone furoate, OT+S) for 12 weeks. Full psychophysical olfactory testing was performed before and after treatment using the "Sniffin' Sticks" test battery (with results for odour threshold, discrimination, identification, and composite "TDI").
resultsA total of 144 patients completed the study: 52 OT, 42 OT+S, 50 OT+VA. The majority of patients had post-infective OD. There were no significant differences between groups in age/sex. There were statistically significant improvements in each subtest (T/D/I) and composite scores (TDI) within each treatment regimen. Across groups, there was a significant interaction between treatment and time (controlling for baseline characteristics) for odour threshold, F(2, 139) = 3.2, p = 0.044, with the largest improvement being seen in the OT+VA group. Further, the greatest proportion of patients reached clinically significant improvement within the OT+VA group (T/D/I/TDI), but this did not reach statistical significance.
conclusionIntranasal VA may be of benefit in treating OD. Further large-scale randomised trials are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.